S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Determine the difference in effects of standard daunorubicin plus Cytarabine (AraC) vs. standard idarubicin plus AraC
Acute Myeloid Leukemia (AML)
- Greater than 18 and less than 60 years of age.
- Have previously untreated Acute Myeloid Leukemia (AML).
- Must not be pregnant or nursing.
18 - 60
Healthy Volunteers Needed
Duration of Participation
Up to 5 years after registration.
Knight Clinical Trials Office Information Line
Southwest Oncology Group (SWOG)